Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.42 - $4.66
Previous CloseN/A
Volume346.43K
Average Volume (3M)1.67M
Market Cap
$267.46M
Enterprise Value$240.43M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 07, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding88,858,610
10 Day Avg. Volume1,598,420
30 Day Avg. Volume1,666,673
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1391.49
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.02K
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$22.00Price Target Upside628.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
aTyr Pharma News
PremiumCompany Announcements
aTyr Pharma’s Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
aTyr Pharma Reports 2024 Results and Strategic Progress---
Bulls Say, Bears Say
Bulls Say
Peer-Reviewed PublicationATYR announced publication of data supporting efzofitimod's immunomodulatory activity in Science Translational Medicine, which is a pre-eminent peer-reviewed scientific journal.
Phase 3 TrialsEfzofitimod's Phase 3 study design and past Phase 2 data suggest a good chance of positive trial outcomes.
Trial ExecutionThe lack of any major surprises in the baseline characteristics provide incremental reassurance on trial execution.
Bears Say
Market PullbackATyr's stock has pulled back with the broader market, and this is seen as a buying opportunity due to clear positive Phase 2 data and lack of competitive pressure.
Potential Conflict Of InterestThere is a potential conflict of interest as Wells Fargo Securities seeks business relationships with companies covered in its research reports.
Steroid Reduction ConcernsSome investors may worry that the required 3mg difference in steroid reduction vs. placebo represents a relatively larger percentage against a 10.55mg baseline in Ph 3 than the 13.2mg baseline from Ph 1/2.
---
Ownership Overview
2.58% Insiders
29.37% Mutual Funds
<0.01% Other Institutional Investors
63.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $1.42 and its highest was $4.66 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $267.46M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is May 07, 2025 which is in 20 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Mar 13, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.226 by $0.046.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.19.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 88,858,610 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.226. Following the earnings report the stock price went down -0.501%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
---
aTyr Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (628.48% Upside)
$22.00 (628.48% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 549.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.88%
12-Months-Change
Fundamentals
Return on Equity
-79.69%
Trailing 12-Months
Asset Growth
-19.67%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
---
ATYR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Read More>---
ATYR Stock 12 Month Forecast
Average Price Target
$22.00
▲(628.48% Upside)
Technical Analysis
Arcturus Therapeutics
―
Olema Pharmaceuticals
―
ATAI Life Sciences
―
Monte Rosa Therapeutics
―
Aura Biosciences Inc
―
Best Analysts Covering ATYR
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+63.60%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +63.60% per trade.
---